YOU ARE HERE: References
References
Adang, A. E.; Hermkens, P. H. (2001). The Contribution of Combinatorial Chemistry to Lead Generation: An Interim Analysis. Curr. Med. Chem. 8, 985-998.
al-Obeidi, F.; Hruby, V. J.; Sawyer, T. K. (1998). Peptide and Peptidomimetic Libraries. Molecular Diversity and Drug Design. Mol. Biotechnol. 9, 205-223.
Aleksandrova, I. Y.; Gol'dfarb, V. L.; Khromov-Borisov, N. V.; Brovtsyna, N. B. (1976). Investigation of the Conformations of the Diamides of Imidazole- and Pyrazoledicarboxylic Acids. Zh. Org. Khim. 12, 1109-1115.
Anonymous (1972). Glycarbylamide; Revocation. Fed. Regist. 37, 5491.
Balkenhohl, F.; von dem Bussche-Hünnefeld, C.; Lansky, A.; Zechel, C. (1996). Combinatorial Synthesis of Small Organic Molecules. Angew. Chem. Int. Ed. Engl. 35, 2288-2337.
Baures, P. W. (1999). Heterocyclic HIV-1 Protease Inhibitors. Org. Lett. 1, 249-252.
Baures, P. W.; Rush, J. R.; Wiznycia, A. V.; Desper, J.; Helfrich, B. A.; Beatty, A. M. (2002). Intramolecular Hydrogen Bonding and Intermolecular Dimerization in the Crystal Structures of Imidazole-4,5-dicarboxylic Acid Derivatives. Cryst. Growth Des. 2, 653-664.
Baures, P. W. (2005). A search of PubChem Compound in January, 2005, for "imidazole dicarboxamide" identified 53 examples of related structures. Some of these compounds have links to PubMed abstracts detailing their published biological activity, but others that we now know to be biologically active have no such links or data present.
Bichevaya, N. K.; Chebotar, N. A.; Aleksandrova, I. Y.; Stepanov, I. I.; Klement'ev, B. I.; Sapronov, N. S. (1999). Antifein Derivatives Protect Embryos from Chloridine-Induced Teratogenesis. Russ. J. Develop. Biol. 30, 259-263.
Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I. (2003). Hit and Lead Generation: Beyond High-throughput Screening. Nat. Rev. Drug Discov. 2, 369-378.
Bogoslavskaya, S. I.; Brovtsina, N. V.; Chromov-Borisov, N. V.; Borodkin, Y. S. (1980). Effect of Structural Features of Some Alkyl Derivatives of Imidazole- and Pyrazole-Dicarboxylic Acid Diamides on the Body's Respiratory Function. Russ. Pharmacol. Toxicol. 43, 202-207.
Borodkin, Y. S.; Shabanov, P. D.; Lapina, I. A.; Yaitchnikov, I. K. (1984). Effects of Antifeins (Memory Affecting Agents) on Behavior, Brain Infraslow Activity and Temperature. Activ. Nerv. Sup. 26, 97-102.
Bouck, K. J.; Rasmussen, P. G. (1993). Synthesis and Characterization of Polyamides Containing Imidazole: Intramolecular Hydrogen Bonding and Constitutional Isomerism. Macromolecules 26, 2077-2084.
Burgess, K. (2001). Solid-Phase Syntheses of β-Turn Analogues to Mimic or Disrupt Protein-Protein Interactions. Acc. Chem. Res. 34, 826-835.
Bursavich, M. G.; Rich, D. H. (2002). Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Conformational Ensembles. J. Med. Chem. 45, 541-558.
Cambridge Discovery Chemical (2001). A news release about the purchase of Cambridge Discover Chemical by Signature BioScience can be found at the following link: http://www.bizjournals.com/eastbay/stories/2001/07/16/daily12.html
Carpy, A. J.; Marchand-Geneste, N. (2003). e-Molecular Shapes and Properties. SAR QSAR Environ. Res. 14, 329-337.
Chen, H.-M.; Hosmane, R. S.; Baldisseri, D. M. (2000). Synthesis of a Novel Ring-Expanded Nucleoside Analog Containing the Imidazo[4,5-e][1,3]diazepine Ring System With a Guanidinocarbamoyl-Substituted Cyclopropylidene Group in Place of a Sugar Moiety. J. Het. Chem. 37, 951-953.
Chen, H.-M.; Hosmane, R. S. (2001). Synthesis of a Novel Ring-Expanded ("Fat") Nucleotide Analog of Phosphonomethoxyethylguanine (PMEG) Containing the Imidazo[4,5-e][1,3]diazepine Ring System. J. Het. Chem. 38, 1313-1315.
Cherry, M.; Williams, D. H. (2004). Recent Kinase and Kinase Inhibitor X-ray Structures: Mechanisms of Inhibition and Selectivity Insights. Curr. Med. Chem. 11, 663-673.
Cochran, A. G. (2000). Antagonists of Protein-Protein Interactions. Chem. Biol. 7, R85-R94.
Crespo, M. I.; Pages, L.; Vega, A.; Segarra, V.; Lopez, M.; Domenech, T.; Miralpeix, M.; Beleta, J.; Ryder, H.; Palacios, J. M. (1998). Design, Synthesis, and Biological Activities of New Thieno[3,2-d]pyrimidines as Selective Type 4 Phosphodiesterase Inhibitors. J. Med. Chem. 41, 4021-4035.
Cuckler, A. C.; Chapin, L. R.; Malanga, C. M.; Rogers, E. F.; Becker, H. J.; Clark, R. L.; Leanza, W. J.; Pessolano, A. A.; Shen, T. Y.; Sarett, L. H. (1958). Antiparasitic drugs. II. Anticoccidial Activity of 4,5-Imidazoledicarboxamide and Related Compounds. Proc. Soc. Exptl. Biol. Med. 98, 167-70.
Cytection (2001). A description of PrimeCyte's proprietary technology is found at the following link: http://www.ppdi.com/corporate/news/detail.htm?ID=73975
Dancey, J.; Sausville, E. A. (2003). Issues and Progress With Protein Kinase Inhibitors for Cancer Treatment. Nature Rev. Drug. Disc. 2, 297-313.
Drummer, H. E.; Wilson, K. A.; Poumbourios, P. (2002). Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81. J. Virol. 76, 11143-11147.
Eliseev, A. V.; Lehn, J. M. (1999). Dynamic Combinatorial Chemistry: Evolutionary Formation and Screening of Molecular Libraries. Curr. Top. Microbiol. Immunol. 243, 159-172.
Engh, R. A.; Bossemeyer, D. (2002). Structural Aspects of Protein Kinase Control-Role of Conformational Flexibility. Pharmacol. Therap. 93, 99-111.
Fenniri, H. (2000). Combinatorial Chemistry. A Practical Approach, Oxford Press, Oxford, England.
Fischer, P. M. (2003). The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review. Curr. Protein Pept. Sci. 4, 339-356.
Floyd, C. D.; Leblanc, C.; Whittaker, M. (1999). Combinatorial Chemistry as a Tool for Drug Discovery. Prog. Med. Chem. 36, 91-168.
García-Echeverría, C.; Traxler, P.; Evans, D. B. (2000). ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases. Med. Res. Rev. 20, 28-57.
Goldberg, D. R.; Butz, T.; Cardozo, M. G.; Eckner, R. J.; Hammach, A.; Huang, J.; Jakes, S.; Kapadia, S.; Kashem, M.; Lukas, S.; Morwick, T. M.; Panzenbeck, M.; Patel, U.; Pav, S.; Peet, G. W.; Peterson, J. D.; Prokopowicz, A. S., III; Snow, R. J.; Sellati, R.; Takahashi, H.; Tan, J.; Tschantz, M. A.; Wang, X.-J.; Wang, Y.; Wolak, J.; Xiong, J.; Moss, N. (2003). Optimization of 2-Phenylaminoimidazo[4,5-h]isoquinolin-9-ones: Orally Active Inhibitors of lck Kinase. J. Med. Chem. 46, 1337-1349.
Golebiowski, A.; Klopfenstein, S. R.; Portlock, D. E. (2001). Lead Compounds Discovered From Libraries. Curr. Opin. Chem. Biol. 5, 273-284.
Goodnow, R. A., Jr,; Guba, W.; Haap, W. (2003). Library Design Practices for Success in Lead Generation with Small Molecule Libraries. Comb. Chem. High Throughput Screen. 6, 649-660.
Gorse, D.; Rees, A.; Kaczorek, M.; Lahana, R. (1999). Molecular Diversity and Its Analysis. Drug Discov. Today 4, 257-264.
Gorse, D.; Lahana, R. (2000). Functional Diversity of Compound Libraries. Curr. Opin. Chem. Biol. 4, 287-294.
Grant, S.; Roberts, J. D. (2003). The Use of Cyclin-Dependent Kinase Inhibitors Alone or In Combination With Established Cytotoxic Drugs in Cancer Chemotherapy. Drug Resist. Updates 6, 15-26.
Gray, N. S. (1999). ATP-Site Directed Inhibitors of Cyclin-Dependent Kinases. Curr. Med. Chem. 6, 859-875.
Gray, N. S. (2001). Combinatorial Libraries and Biological Diversity. Curr. Opin. Neurobiol. 11, 608-614.
Hadlock, K. G.; Lanford, R. E.; Perkins, S.; Rowe, J.; Yang, Q.; Levy, S.; Pileri, P.; Abrignani, S.; Foung, S. K. (2000). Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes. J. Virol. 74, 10407-10416.
Haesslein, J.-L.; Jullian, N. (2002). Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future. Curr. Top. Med. Chem. 2, 1037-1050.
Hann, M. M.; Leach, A. R.; Harper, G. (2001). Molecular Complexity and Its Impact on the Probablility of Finding Leads for Drug Discovery. J. Chem. Inf. Comput. Sci. 41, 856-864.
Harmse, L.; van Zyl, R.; Gray, N.; Schultz, P.; Leclerc, S.; Meijer, L.; Doerig, C.; Havlik, I. (2001). Structure-activity Relationships and Inhibitory Effects of Various Purine Derivatives on the In Vitro Growth of Plasmodium Falciparum. Biochem. Pharmacol. 62, 341-348.
Harper, G.; Pickett, S. D.; Green, D. V. (2004). Design of a Compound Screening Collection for Use in High Throughput Screening. Comb. Chem. High Throughput Screen. 7, 63-70.
Higginbottom, A.; Quinn, E. R.; Kuo, C.-C.; Flint, M.; Wilson, L. H.; Bianchi, E.; Nicosia, A.; Monk, P. N.; McKeating, J. A.; Levy, S. (2000). Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2. J. Virol. 74, 3642-3649.
Hofbauer, C.; Lohninger, H.; Aszodi, A. (2004). SURFCOMP: A Novel Graph-based Approach to Molecular Surface Comparison. J. Chem. Inf. Comput. Sci. 44, 837-847.
Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. (2001). Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 44, 4615-4627.
Hruby, V. J. (1993). Conformational and Topographical Considerations in the Design of Biologically Active Peptides. Biopolymers 33, 1073-1082.
Hruby, V. J.; Shenderovich, M.; Lam, K. S.; Lebl, M. (1996). Design Considerations and Computer Modeling Related to the Development of Molecular Scaffolds and Peptide Mimetics for Combinatorial Chemistry. Mol. Divers. 2, 46-56.
Hruby, V. J.; Li, G.; Haskell-Luevano, C.; Shenderovich, M. (1997). Design of Peptides, Proteins, and Peptidomimetics in Chi Space. Biopolymers 43, 219-266.
Hruby, V. J.; Balse, P. M. (2000). Conformational and Topographical Considerations in Designing Agonist Peptidomimetics From Peptide Leads. Curr. Med. Chem. 7, 945-970.
Hulsmann, M.; Nickel, P.; Kassack, M.; Schmalzing, G.; Lambrecht, G.; Markwardt, F. (2003). NF449, A Novel Picomolar Potency Antagonist at Human P2X1 Receptors. Eur. J. Pharmacol. 470, 1-7.
Jackson, R. M. (1999). Comparison of Protein-protein Interactions in Serine Protease-inhibitor and Antibody-antigen Complexes: Implications for the Protein Docking Problem. Protein Sci. 8, 603-613.
Janin, J. (2000). Kinetics and Thermodynamics of Protein-Protein Interactions in Protein-Protein Recognition, Kleanthous, C., Ed., pp. 1-32, Oxford University Press, Oxford.
Javitch, J. A. (2004). The Ants go Marching Two by Two: Oligomeric Structure of G-protein-coupled receptors. Mol. Pharmacol. 66, 1077-1082.
Back to the Top
Khersonsky, S. M.; Chang, Y. T. (2004). Forward Chemical Genetics: Library Scaffold Design. Comb. Chem. High Throughput Screen. 7, 645-652.
Kim; Kyoung, M.; Cho, Y.-H.; Kim, J. M.; Chun, M. W.; Lee, S. K.; Lim, Y.; Lee, C.-H. (2003). Inhibition of Cell-cycle Progression in Human Promyelocytic Leukemia HL-60 Cells by MCS-C2, Novel Cyclin-dependent Kinase Inhibitor. J. Microbiol. Biotechnol. 13, 607-612.
Kitadokoro, K.; Bordo, D.; Galli, G.; Petracca, R.; Falugi, F.; Abrignani, S.; Grandi, G.; Bolognesi, M. (2001). CD81 Extracellular Domain 3D Structure: Insight Into the Tetraspanin Superfamily Structural Motifs. EMBO J . 20, 12-18.
Kitadokoro, K.; Ponassi, M.; Galli, G.; Petracca, R.; Falugi, F.; Grandi, G.; Bolognesi, M. (2002). Subunit Association and Conformational Flexibility in the Head Subdomain of Human CD81 Large Extracellular Loop. Biol Chem. 383, 1447-1452.
Klein, C. T.; Kaiblinger, N.; Wolschann, P. (2002). Internally Defined Distances in 3D-Quantitative Structure-activity Relationships. J. Comput. Aided Mol. Des. 16, 79-93.
Knockaert, M.; Lenormand, P.; Gray, N.; Schultz, P.; Pouysségur, J.; Meijer, L. (2002). p42/p44 MAPKs are Intracellular Targets of the CDK Inhibitor Purvalanol. Oncogene 21, 6413-6424.
Kolb, V. M. (1998). Biomimicry as a Basis for Drug Discovery. Prog. Drug Res. 51, 185-217.
Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; Hamilton, A. D. (2002). Development of a Potent Bcl-x(L) Antagonist Based on α-Helix Mimicry. J. Am. Chem. Soc. 124, 11838-11839.
Langer, T.; Krovat, E. M. (2003). Chemical Feature-based Pharmacophores and Virtual Library Screening for Discovery of New Leads. Curr. Opin. Drug Discov. Devel. 6, 370-376.
Li, B.; Liu, Y.; Uno, T.; Gray, N. (2004). Creating Chemical Diversity to Target Protein Kinases. Comb. Chem. High Throughput Screen. 7, 453-472.
Lipinski, C. A., Lombardo, F.; Dominy, B. W.; Feeney, P. J. (1997). Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Delivery Res. 23, 3-25.
Lipinski, C. A. (2000). Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. J. Pharmacol. Toxicol. Methods 44, 235-249.
Lo Conte, L.; Chothia, C.; Janin, J. (1999). The Atomic Structure of Protein-protein Recognition Sites. J. Mol. Biol. 285, 2177-2198.
Ma, B.; Wolfson, H. J.; Nussinov, R. (2001). Protein Functional Epitopes: Hot Spots, Dynamics, and Combinatorial Libraries. Curr. Opin. Struct. Biol. 11, 364-369.
Malumbres, M.; Barbacid, M. (2001). To Cycle or Not to Cycle: A Critical Decision in Cancer. Nature Rev. Cancer 1, 222-231.
Mareel, M.; Leroy, A. (2003). Clinical, Cellular, and Molecular Aspects of Cancer Invasion. Physiol. Rev. 83, 337-376.
Marshall, G. R. (1993). A Heirarchical Approach to Peptidomimetic Design. Tetrahedron 49, 3547-3558.
Mason, J. S.; Hermsmeier, M. A. (1999a). Diversity Assessment. Curr. Opin. Chem. Biol. 3, 342-349.
Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. (1999b). New 4-Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the Method and Applications, Including a Novel Approach to the Design of Combinatorial Libraries Containing Privileged Substructures. J. Med. Chem. 26, 3251-3264.
McCain, D. F.; Wu, L.; Nickel, P.; Kassack, M. U.; Kreimeyer, A.; Gagliardi, A.; Collins, D. C; Zhang, Z. Y. (2004). Suramin Derivatives as Inhibitors and Activators of Protein-tyrosine Phosphatases. J. Biol. Chem. 279, 14713-14725.
McCormick, F. (2000). Small-Molecule Inhibitors of Cell Signaling. Curr. Opin. Biotech. 11, 593-597.
McDonald, V.; Stables, R.; Warhurst, D. C.; Barer, M. R.; Blewett, D. A.; Chapman, H. D.; Connolly, G. M.; Chiodini, P. L.; McAdam, K. P. (1990). In Vitro Cultivation of Cryptosporidium parvum and Screening for Anticryptosporidial Drugs. Antimicrob Agents Chemother. 34, 1498-1500.
MDS Panlabs, 11804 North Creek Parkway South, Bothell, WA 98011. E-mail: pharminfo@panlabs.com; Internet: www.panlabs.com.
Muegge, I.; Heald, S. L.; Brittelli, D. (2001). Simple Selection Criteria for Drug-Like Chemical Matter. J. Med. Chem. 44, 1841-1846.
Milligan, G. (2004). G protein-coupled Receptor Dimerization: Function and Ligand Pharmacology. Mol. Pharmacol. 66, 1-7.
Nicke, A.; Kerschensteiner, D.; Soto, F. (2005). Biochemical and Functional Evidence for Heteromeric Assembly of P2X and P2X Subunits. J. Neurochem. 92, 925-933.
Nilakantan, R.; Immermann, F.; Harki, K. (2002). A Novel Approach to Combinatorial Library Design. Comb. Chem. & High Through. Screen. 5, 105-110.
Noble, M. E.; Endicott, J. A.; Johnson, L. N. (2004). Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science 303, 1800-1805.
Orner, B. P.; Ernst, J. T.; Hamilton, A. D. (2001). Toward Proteomics: Terphenyl Derivatives as Structural and Functional Mimics of Extended Regions of an ?-Helix. J. Am. Chem. Soc. 123, 5382-5383.
Perchellet, E. M.; Perchellet, J.-P.; Baures, P. W. (2005) J. Med. Chem. 48, 5955-5965.
Petracca, R.; Falugi, F.; Galli, G.; Norais, N.; Rosa, D.; Campagnoli, S.; Burgio, V.; Di Stasiko, E.; Giardina, B.; Houghton, M.; Abrignani, S.; Grandi, G. (2000). Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding. J. Virol. 74, 4824-4830.
Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A. J.; Houghton, M.; Rosa, D.; Grandi, G.; Abrignani, S. (1998). Binding of Hepatitis C Virus to CD81. Science, 282, 938-941.
Polanski, J.; Walczak, B. (2000). The Comparative Molecular Surface Analysis (COMSA): A Novel Tool for Molecular Design. Comput. Chem. 24, 615-625.
Polanski, J.; Gieleciak, R. (2003). Comparative Molecular Surface Analysis: A Novel Tool for Drug Design and Molecular Diversity Studies. Mol. Divers. 7, 45-59.
PrimeCyte, Inc. (2002). A news release about the purchase of PrimeCyte, Inc. by Signature BioScience in 2002 can be found at the following link: http://www.bizjournals.com/eastbay/stories/2002/02/04/daily40.html
Protein Design Labs, (2001). A news release about the purchase of the small molecule group from Protein Design Labs by Signature BioScience in late 2001 can be found at the following link: http://www.bizjournals.com/eastbay/stories/2002/01/28/daily33.html
Reayi, A.; Hosmane, R. S. (2004a). Inhibition of Adenosine Deaminase by Novel 5:7 Fused Heterocycles Containing the Imidazo[4,5-e][1,2,4]triazepine Ring System: A Structure-activity Relationship Study. J. Med. Chem. 47, 1044-1050.
Reayi, A.; Hosmane, R. S. (2004b). Inhibitors of Adenosine Deaminase: Continued Studies of Structure-activity Relationships in Analogues of Coformycin. Nucleosides Nucleotides Nucleic Acids. 23, 263-271.
Reikhardt, B. A.; Kulikova, O. G. (1994). Participation of Adenosine Receptors in Antifein-Mediated Regulation of Neuronal Chromatin. Biochemistry (Moscow) 59, 1059-1063.
Rush, J. R.; Sandstrom, S. L.; Yang, J.; Davis, R.; Prakash, O.; Baures, P. W. (2005). Intramolecular Hydrogen Bond Strength and pKa Determination of N,N'-Disubstituted Imidazole-4,5-dicarboxamides. Org. Lett. 7, 135-138.
Sausville, E. A. (2003). Cyclin-Dependent Kinase Modulators Studied at the NCI: Pre-Clinical and Clinical Studies. Curr. Med. Chem. Anti-Cancer Agents. 3, 47-56.
Scapin, G. (2002). Structural Biology in Drug Design: Selective Protein Kinase Inhibitors. Drug Discov. Today 7, 601-611.
Senderowitz, H.; Rosenfeld, R. (2001). Design of Structural Combinatorial Libraries That Mimic Biological Motifs. J. Rec. Signal Trans. Res. 21, 489-506.
Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. (2000). Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. J. Med. Chem. 43, 1-18.
Siemion, I. Z.; Cebrat, M.; Kluczyk, A. (2004) The Problem of Amino Acid Complementarity and Antisense Peptides. Curr. Protein Pept. Sci. 5, 507-527.
Signature BioScience, Inc. (2003). A news release regarding the unexpected closure of Signature BioScience is found at the following link: http://www.bizjournals.com/industries/health_care/biotechnology/2003/04/28/sanfrancisco_story3.html
Thorpe, D. S. (2000). Forecasting Roles of Combinatorial Chemistry in the Age of Genomically Derived Drug Discovery Targets. Comb. Chem. High Throughput Screen. 3, 421-436.
Toledo, L. M.; Lydon, N. B.; Elbaum, D. (1999). The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors. Curr. Med. Chem. 6, 775-805.
Toogood, P. L. (2002). Inhibition of Protein-Protein Association by Small Molecules: Approaches and Progress. J. Med. Chem. 45, 1543-1558.
Traxler, P.; Furet, P. (1999). Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacol. Ther. 82, 195-206.
Vaino, A. R.; Janda, K. D. (2000). Solid-Phase Organic Synthesis: A Critical Understanding of the Resin. J. Comb. Chem. 2, 579-596.
VanCompernolle, S. E.; Wiznycia, A. V.; Rush, J. R.; Dhanasekaran, M.; Baures, P. W.; Todd, S. C. (2003). Small Molecule Inhibition of Hepatitis C Virus E2 Binding to CD81. Virology 314, 371-380.
Weber, L. (2000). High-Diversity Combinatorial Libraries. Curr. Opin. Chem. Biol. 4, 295-302.
Wiznycia, A. V.; Helfrich, B. A.; Baures, P. W. (2002). An Improved Method for the Synthesis of Dissymmetric N,N'-Disubstituted Imidazole-4,5-dicarboxamides. J. Org. Chem. 67, 7151-7154.
Wiznycia, A. V.; Rush, J. R.; Baures, P. W. (2004). Synthesis of Symmetric Bis-imidazole-4,5-dicarboxamides Bearing Amino Acids. J. Org. Chem. 69, 8489-8491.
Wunschmann, S.; Medh, J. D.; Klinzmann, D.; Schmidt, W. N.; Stapleton, J. T. (2000). Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor. J. Virol. 74, 10055-10062.
Xu, R. X.; Hassell, A. M.; Vanderwall, D.; Lambert, M. H.; Holmes, W. D.; Luther, M. A.; Rocque, W. J.; Milburn, M. V.; Zhao, Y.; Ke, H.; Nolte, R. T. (2000). Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science 288, 1822-1825.
Yasuda, N.; Iwagami, H.; Nakanishi, E.; Nakamiya, T.; Sasaki, Y.; Murata, T. (1983). Synthesis and Antibacterial Activity of 6- and 7-[2-(5-Carboxyimidazole-4-carboxamido)phenylacetamido]-penecillins and Cephalosporins. J. Antibiotics 36, 242-249.
Yasuda, N.; Nakamura, A.; Tsuboi, M. (1987). Intramolecular Hydrogen Bonding in Imidazole-4(5)-alkoxycarbonyl-5(4)-carboxamide Derivatives. J. Het. Chem. 24, 303-307.
Young, S. S.; Ge, N. (2004). Design of Diversity and Focused Combinatorial Libraries in Drug Discovery. Curr. Opin. Drug Discov. Devel. 7, 318-324.
Zhang, N.; Chen, H. M.; Koch, V.; Schmitz, H.; Liao, C. L.; Bretner, M.; Bhadti, V. S.; Fattom, A. I.; Naso, R. B.; Hosmane, R. S.; Borowski, P. (2003a). Ring-expanded ("Fat") Nucleoside and Nucleotide Analogues Exhibit Potent In Vitro Activity Against Flaviviridae NTPases/helicases, Including Those of the West Nile Virus, Hepatitis C Virus, and Japanese Encephalitis Virus. J. Med. Chem. 46, 4149-4164.
Zhang, N.; Chen, H. M.; Koch, V.; Schmitz, H.; Minczuk, M.; Stepien, P.; Fattom, A. I.; Naso, R. B.; Kalicharran, K.; Borowski, P.; Hosmane, R. S. (2003b). Potent Inhibition of NTPase/helicase of the West Nile Virus by Ring-expanded ("Fat") Nucleoside Analogues. J. Med. Chem. 46, 4776-4789.
Zutshi, R.; Brickner, M.; Chmielewski, J. (1998). Inhibiting the Assembly of Protein-Protein Interfaces. Curr. Opin. Chem. Biol. 2, 62-66.
Back to the Top